Sign in

Private company

CHINOOK THERAPEUTICS, INC.

CHINOOK THERAPEUTICS, INC. is an American pharmaceutical preparations company based in Berkeley.2

Last updated Oct 21, 2026.

Overview

  • IndustryPharmaceutical Preparations2
  • HeadquartersBerkeley, United States2
  • Incorporated inDE3
  • Business address400 Fairview Avenue North, Suite 900, Seattle, Wa 981093
  • Filer categoryLarge accelerated filer3
  • Legal formCorporation2
  • LEI549300X0O3003W5QYQ482
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O THE CORPORATION TRUST COMPANY, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 49764112

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-3020.3%Operating margin4
-3065.7%Net margin4
-88.1%Revenue growth, 20224
-42.5%Return on equity4
-$119.1MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Research and development97¢$141.2M
  • Income tax3¢$4.3M

Out of $6.1M in revenue.4 The company lost money this year.

Financial statements

Revenue564$6.1M in 2022−88% since 2016
0$20.0M$40.0M$60.0M2016: $50.7M$50.7M20162017: $17.2M$17.2M2017−66%2018: $15.1M$15.1M2018−12%2019: $17.3M$17.3M2019+14%2020: $827.0K$827.0K2020−95%2021: $51.6M$51.6M2021+6142%2022: $6.1M$6.1M2022−88%
Operating income5674-$185.1M in 2022+158% since 2016
-$200.0M-$150.0M-$100.0M-$50.0M02016: -$71.9M-$71.9M20162017: -$106.5M-$106.5M2017+48%2018: -$101.4M-$101.4M2018−5%2019: -$20.0M-$20.0M2019−80%2020: -$56.2M-$56.2M2020+182%2021: -$99.0M-$99.0M2021+76%2022: -$185.1M-$185.1M2022+87%
Net income5674-$187.9M in 2022+106% since 2016
-$200.0M-$150.0M-$100.0M-$50.0M02016: -$91.1M-$91.1M20162017: -$91.9M-$91.9M2017+1%2018: -$95.4M-$95.4M2018+4%2019: -$46.5M-$46.5M2019−51%2020: -$81.6M-$81.6M2020+75%2021: -$102.9M-$102.9M2021+26%2022: -$187.9M-$187.9M2022+83%
Fiscal year2016201720182019202020212022
Revenue$50.7M5$17.2M6$15.1M6$17.3M6$827.0K4$51.6M4$6.1M4
Research and development$87.7M5$89.4M6$75.8M6$17.0M7$36.1M4$97.0M4$141.2M4
Operating income-$71.9M5-$106.5M6-$101.4M6-$20.0M7-$56.2M4-$99.0M4-$185.1M4
Interest
Income before tax-$100.8M4-$183.5M4
Income tax$21.5M5-$11.4M6-$783.0K6-$35.0K10-$2.0M4$2.1M4$4.3M4
Net income-$91.1M5-$91.9M6-$95.4M6-$46.5M7-$81.6M4-$102.9M4-$187.9M4
Earnings per share-$6.204-$2.264-$2.924
Earnings per share (diluted)-$6.204-$2.264-$2.924
Shares (weighted, basic)45.6M shares464.4M shares4
Shares (weighted, diluted)45.6M shares464.4M shares4

Compare CHINOOK THERAPEUTICS, INC. with another company

Corporate structure

CHINOOK THERAPEUTICS, INC. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of CHINOOK THERAPEUTICS, INC.

  • CHINOOK THERAPEUTICS, INC. Berkeley, California, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What CHINOOK THERAPEUTICS, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$24.1M4 Dec 31, 2022$23.1M4 Dec 31, 2021+4.4%
Accumulated depreciation$7.2M4 Dec 31, 2022$4.1M4 Dec 31, 2021+73.9%
Property and equipment, net$16.9M4 Dec 31, 2022$18.9M4 Dec 31, 2021−10.7%
Operating-lease assets (leased space)$49.0M4 Dec 31, 2022$55.4M4 Dec 31, 2021−11.6%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$115.4M4 Dec 31, 2022$181.7M4 Dec 31, 2021−36.5%
Marketable securities, current$262.9M4 Dec 31, 2022$105.1M4 Dec 31, 2021+150.1%
Marketable securities, non-current$7.0M4 Dec 31, 2022$68.2M4 Dec 31, 2021−89.8%
Debt securities available for sale$269.9M4 Dec 31, 2022$173.3M4 Dec 31, 2021+55.7%
Stakes in other companies (equity method)$4.1M4 Dec 31, 2022$8.2M4 Dec 31, 2021−50.4%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$117.0K4 Dec 31, 2022$117.0K4 Dec 31, 20210%
Intangible assets, net (excluding goodwill)$60.8M4 Dec 31, 2022$62.6M4 Dec 31, 2021−2.8%
Finite-lived intangibles, gross$28.1M4 Dec 31, 2022$28.1M4 Dec 31, 20210%
Accumulated amortization$3.8M4 Dec 31, 2022$2.1M4 Dec 31, 2021+81.7%
Finite-lived intangibles, net$24.3M4 Dec 31, 2022$26.0M4 Dec 31, 2021−6.6%

Leadership

Who has led CHINOOK THERAPEUTICS, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Stephen T. Isaacs2015–2020
  2. Eric Dobmeier2020–2023

President

  1. Stephen T. Isaacs2015–2020
  2. Eric Dobmeier2020–2023

Chief financial officer

  1. Jennifer Lew2018–2019
  2. William G. Kachioff2020
  3. Eric Bjerkholt2020–2023

Chief operating officer

  1. Gregory W. Schafer2015–2018
  2. Tom Frohlich2021–2023
20202025
Board members and other officers (31)

Former names

  • ADURO BIOTECH, INC.Dec 5, 2011 to Oct 15, 20203
  • ADURO BIOTECHMay 8, 2008 to Apr 22, 20113

Timeline

  1. Aug 11, 20238-K Ended a material agreement; Completed an acquisition or sale; Listing notice or transfer49
  2. Aug 3, 20238-K Shareholder vote50
  3. Jul 28, 20238-K Other events51
  4. Jun 20, 20238-K Other events52
  5. Jun 15, 20238-K Executive or director change; Shareholder vote53
  6. Jun 12, 20238-K Entered a material agreement; Regulation FD disclosure54
  7. Jun 12, 20238-K Other events55
  8. May 9, 20238-K Results of operations56
  9. Apr 13, 20238-K Executive or director change; Regulation FD disclosure57
  10. Mar 13, 20238-K Regulation FD disclosure58
  11. Feb 27, 20238-K Results of operations59
  12. Feb 24, 20238-K Bylaws or fiscal year changed60
  13. Oct 7, 2020New chief executive Eric Dobmeier becomes CEO13
  14. Apr 14, 2015New chief executive Stephen T. Isaacs becomes CEO14

Calendar

When it reported results

  1. May 9, 2023Reported quarterly or annual results56
  2. Feb 27, 2023Reported quarterly or annual results59
  3. Nov 10, 2022Reported quarterly or annual results61
  4. Aug 8, 2022Reported quarterly or annual results62
  5. May 12, 2022Reported quarterly or annual results63
  6. Mar 17, 2022Reported quarterly or annual results64
  7. Nov 8, 2021Reported quarterly or annual results65

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

183 filings to the SEC since October 2021: 2 annual reports, 6 quarterly reports, 24 major events, 90 insider forms, 19 large holders, 42 other. The latest 20:

  1. Nov 22, 2023SC 13D/A EDGAR
  2. Aug 21, 202315-12G EDGAR
  3. Aug 16, 2023EFFECT EDGAR
  4. Aug 11, 20234 FORM 4 SUBMISSION EDGAR
  5. Aug 11, 20234 FORM 4 SUBMISSION EDGAR
  6. Aug 11, 20234 FORM 4 SUBMISSION EDGAR
  7. Aug 11, 20234 FORM 4 SUBMISSION EDGAR
  8. Aug 11, 20234 FORM 4 SUBMISSION EDGAR
  9. Aug 11, 20234 FORM 4 SUBMISSION EDGAR
  10. Aug 11, 20234 FORM 4 SUBMISSION EDGAR
  11. Aug 11, 20234 FORM 4 SUBMISSION EDGAR
  12. Aug 11, 20234 FORM 4 SUBMISSION EDGAR
  13. Aug 11, 20234 FORM 4 SUBMISSION EDGAR
  14. Aug 11, 20234 FORM 4 SUBMISSION EDGAR
  15. Aug 11, 20234 FORM 4 SUBMISSION EDGAR
  16. Aug 11, 2023S-8 POS EDGAR
  17. Aug 11, 2023S-8 POS EDGAR
  18. Aug 11, 2023S-8 POS EDGAR
  19. Aug 11, 2023S-8 POS EDGAR
  20. Aug 11, 2023S-8 POS EDGAR

The 183 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

42 open-market trades by officers, directors and large owners since October 2021: 4 buys and 38 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 1, 2023King Andrew JamesChief Scientific OfficerSale1,168$39.03$45.6KForm 4
May 30, 2023Greenman William MarinerDirectorSale1,155$23.30$26.9KForm 4
Apr 24, 2023DOBMEIER ERICPresident, CEOSale25,000$21.61$540.3KForm 4
Apr 17, 2023Jerel DavisDirectorSale295,808$20.75$6.1MForm 4
Apr 4, 2023Krishnan MaheshDirectorSale924$23.01$21.3KForm 4
Apr 3, 2023King Andrew JamesChief Scientific OfficerSale5,000$23.34$116.7KForm 4
Mar 1, 2023Jerel DavisDirectorSale400,000$22.75$9.1MForm 4
Feb 10, 2023BJERKHOLT ERICChief Financial OfficerSale857$23.75$20.4KForm 4
Feb 10, 2023DOBMEIER ERICPresident, CEOSale8,097$23.75$192.3KForm 4
Feb 10, 2023Frohlich TomChief Operating OfficerSale3,700$23.75$87.9KForm 4
Feb 10, 2023King Andrew JamesChief Scientific OfficerSale2,392$23.75$56.8KForm 4
Jan 31, 2023Frohlich TomChief Operating OfficerSale4,566$24.68$112.7KForm 4
Jan 31, 2023BJERKHOLT ERICChief Financial OfficerSale2,891$24.68$71.3KForm 4
Jan 31, 2023King Andrew JamesChief Scientific OfficerSale3,244$24.68$80.1KForm 4
Jan 31, 2023DOBMEIER ERICPresident, CEOSale7,688$24.68$189.7KForm 4
Jan 30, 2023DOBMEIER ERICPresident, CEOSale25,000$24.54$613.5KForm 4
Jan 3, 2023King Andrew JamesChief Scientific OfficerSale10,000$25.82$258.2KForm 4
Dec 13, 2022Frohlich TomChief Operating OfficerSale10,000$25.00$250.0KForm 4
Dec 1, 2022DOBMEIER ERICPresident, CEOSale30,000$22.31$669.3KForm 4
Dec 1, 2022BJERKHOLT ERICChief Financial OfficerSale5,770$22.29$128.6KForm 4

All 42 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How CHINOOK THERAPEUTICS, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARCHINOOK THERAPEUTICS, INC.1
  • CIK0001435049
  • Filer statusLarge accelerated filer1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • Business address400 Fairview Avenue North, Suite 900, Seattle, WA 981091
  • Phone206-485-70511
  • Shares outstanding71,804,977 as of Aug 4, 20239
  • Public float$896.5M as of Jun 30, 20224
  • On EDGAR sinceMay 8, 20081
  • Filings765 in all: 4 (383), 8-K (98), 3 (38), 10-Q (26), SC 13G/A (21), DEFA14A (17), SC 13G (15), 425 (14)1
    All 54 form types

    SC 13D/A (12), CORRESP (11), S-8 (11), S-8 POS (11), UPLOAD (10), 10-K (8), 424B5 (8), D (8), DEF 14A (8), CT ORDER (7), EFFECT (7), 8-K/A (4), S-3 (4), SC 13D (4), 4/A (2), 424B3 (2), 5 (2), DFAN14A (2), DRS/A (2), DRSLTR (2), FWP (2), S-1/A (2), 10-K/A (1), 10-Q/A (1), 144 (1), 15-12G (1), 25-NSE (1), 3/A (1), 424B4 (1), 8-A12B (1), ARS (1), CERTNAS (1), D/A (1), DEFM14A (1), DRS (1), NT 10-K (1), NT 10-Q (1), POS AM (1), POSASR (1), PRE 14A (1), PREM14A (1), REGDEX (1), S-1 (1), S-3ASR (1), S-4 (1), S-4/A (1)

  • Latest filingsAnnual report (10-K) Feb 27, 2023
    Quarterly report (10-Q) Aug 7, 2023
    Proxy statement (DEF 14A) Apr 28, 2023
    Latest 8-K (8-K) Aug 11, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
    SEC EDGAROther events
  52. 52
    SEC EDGAROther events
  53. 53
  54. 54
  55. 55
    SEC EDGAROther events
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75